Linde awards first research grants at Linde Healthcare REALfund event
0
Linde AG /
Linde awards first research grants at Linde Healthcare REALfund event
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Munich, 11 July 2011 - The technology group The Linde Group today announced the
first beneficiaries of the REALfund initiative. The REALfund was set up in the
company´s global business unit Linde Healthcare in 2010 to support novel and
innovative research into the role of gases in three key areas: respiratory
medicine, acute pain management and gas-enabled wound care. Four grantees -
selected from over 30 applications - will receive a total EUR 300,000 in
funding.
"Every day, gases prove invaluable in the treatment of illnesses, " said J. Kent
Masters, Member of the Executive Board of Linde AG and responsible for the
company´s healthcare business. "Therefore research and development is also a key
priority in this area. The REALfund is intended to promote projects relating to
the use of gases in certain therapeutic focus areas of healthcare. The current
REALfund grants cover a wide range of intriguing innovative research."
The funding will support the grantees to continue their research which aims to
develop treatments that benefit patients and caregivers. Dr Alice Margaret Wood,
Birmingham University, is researching how oxygen therapy can help patients with
chronic obstructive pulmonary disease. Professor Gerd Döring, University of
Tübingen, is researching the use of nitric oxide in the treatment of infections
for cystic fibrosis. Professor Arne May, University of Hamburg, is investigating
the effect of oxygen on headaches, including migraines. And Dr Paul Seddon,
Brighton and Sussex University Hospitals NHS Trust, is looking at how new
technology can be used to monitor patients´ oxygen saturation and heart rate
from home rather than in hospital.
The REALfund scientific event in Munich has been attended by the REALfund
grantees, along with top management of Linde AG, and a number of invited experts
and key opinion leaders in respiratory care.
The Linde Healthcare REALfund (REAL = Research, Evolve, Advance, Lead) is a
research fund that develops and fosters promising ideas in healthcare and is
aimed at healthcare practitioners, patient organisations, inventors and
scientists. The fund supports innovative projects that investigate new
applications for gases, devices for safe and effective delivery of gases,
equipment to monitor the effects and success of gas-enabled therapies, and
complementary products and services in this field. Grants are awarded in line
with the complexity of each project and may be as much as EUR 75,000.
The Healthcare business covers Linde´s medical gases, services, devices and care
operations. Here, the Group continues on its steady growth path and achieved
sales of EUR 1.130 bn in the 2010 financial year.
The Linde Group is a world-leading gases and engineering company with around
48,700 employees working in more than 100 countries worldwide. In the 2010
financial year, it achieved sales of EUR 12.868 bn. The strategy of The Linde
Group is geared towards sustainable earnings-based growth and focuses on the
expansion of its international business with forward-looking products and
services. Linde acts responsibly towards its shareholders, business partners,
employees, society and the environment - in every one of its business areas,
regions and locations across the globe. Linde is committed to technologies and
products that unite the goals of customer value and sustainable development.
For more information, see The Linde Group online at http://www.linde.com
Further information:
Press Investor Relations
Uwe Wolfinger Dr Dominik Heger
Telephone: +49.89.35757-1320 Telephone: +49.89.35757-1334
Thomas Eisenlohr
Telephone: +49.89.35757-1330
For further information on the REALfund grantees or the REALfund event, please
contact Anne Mette Schrade using the details below.
Anne Mette Schrade
Linde Healthcare Communications
Phone: +49 89 7446 2247
Mobile: +49 177 876 5135
E-mail:anne-mette.schrade@linde-gas.com
--- End of Message ---
Linde AG
Klosterhofstrasse 1 Munich Germany
WKN: 648300;ISIN: DE0006483001;Index:Prime All Share, HDAX, DAX, CDAX;
Listed: Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse,
Regulierter Markt in Börse Stuttgart,
Regulierter Markt in Bayerische Börse München,
Regulierter Markt in Börse Berlin,
Regulierter Markt in Hanseatische Wertpapierbörse zu Hamburg,
Regulierter Markt in Börse Düsseldorf;
Press Release as PDF:
http://hugin.info/125064/R/1529605/465126.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Linde AG via Thomson Reuters ONE
[HUG#1529605]
DE0006483001
